Although studies in colorectal carcinoma have shown that somatic KRAS mutation is associated with resistance to cetuximab (Khambata-Ford et al, 2007; Lievre et al, 2008), the present study has shown KRAS mutations to be rare in cervical carcinomas. This evidence concerns the gene KRAS and cervical carcinoma.